MPS Powered by Eureka

Current Alzheimer Research

ISSN: 1567-2050 (Print)
eISSN: 1875-5828 (Online)

Current Alzheimer Research publishes peer-reviewed frontier review, research, drug clinical trial studies, letter articles, case reports, systematic reviews, and editorials on all areas of Alzheimer's disease. This multidisciplinary journal will help in understanding the neurobiology, genetics, pathogenesis, diagnosis and treatment strategies of Alzheimer's disease. The journal publishes objective reviews written by experts and leaders actively engaged in research using cellular, molecular, and animal models. The journal also covers original articles on recent research in fast emerging areas of molecular diagnostics, brain imaging, drug development and discovery, and clinical aspects of Alzheimer's disease. Manuscripts are encouraged that relate to the synergistic mechanism of Alzheimer's disease with other dementia and neurodegenerative disorders. Book reviews, meeting reports and letters-to-the-editor are also published. The journal is essential reading for researchers, educators and physicians with interest in age-related dementia and Alzheimer's disease. Current Alzheimer Research provides a comprehensive 'bird's-eye view' of the current state of Alzheimer's research for neuroscientists, clinicians, health science planners, granting, caregivers and families of this devastating disease.

Special Issues With Active Call for Papers

Submission closes on: Dec 10, 2024
Regulation of Immunosenescence in Neurodegenerative Disorders: Mechanisms, Implications, and Therapeutic Strategies

Scope: Growing evidence has suggested that immunosenescence, aging-associated change in immune function, plays a critical role in the progression and severity of neurodegenerative disorders including Alzheimer's disease (AD), Parkinson's disease, Huntington's disease, and multiple sclerosis. This special issue aims to investigate the mechanisms underlying immune cell aging and exhaustion, their role in neuroinflammation, and their contribution to the pathology of neurodegenerative disorders. By focusing on recent advancements in understanding how aging immune cells influence neurodegenerative... see more

Submission closes on: Nov 04, 2024
Perspectives and Dynamic Predictive Factors Related to Mild Cognitive Impairment (MCI) and Alzheimer’s Disease (AD) or Conversion from MCI to AD

Cognitive decline, especially Alzheimer’s disease (AD), is neurodegenerative disorders characterized by the cerebral accumulation of amyloid beta (Aβ) and tau and other proposed pathophysiologies. Mild cognitive impairment (MCI) and AD impair the quality of life of the elderly and pose huge public health burdens to the society. The development of MCI and AD are a consequence of the interaction of genetic and environmental factors including ApoE4 and other genetic risk factors, lifestyle, education level, metabolic... see more

Submission closes on: Oct 31, 2024
Alzheimer's Disease Drug Development

Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of the current state of Alzheimer's disease drug development, identify the challenges, and propose future directions for drug discovery and development. We hope that this collection... see more

Submission closes on: Sep 30, 2024
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders

Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer’s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain tissue of AD patients and also is found across AD animal models. Neuroinflammation has also been shown across different phases of AD pathology. Indeed, from... see more

Submission closes on: Sep 30, 2024
Deep Learning for Advancing Alzheimer's Disease Research

Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our understanding of AD, enabling early diagnosis, predicting disease progression, and developing innovative therapeutic interventions. Authors are invited to submit their original research or review articles... see more

Submission closes on: Sep 04, 2024
Machine learning in neuroimaging of Dementia and normal aging

Application of Artificial Intelligence (AI) in medical imaging has significantly transformed the field of medical diagnostics, enabling faster and more accurate analyses. This Special Issue aims to gather groundbreaking research and innovative applications that leverage AI to advance medical imaging analysis in the field of dementia and normal aging. We welcome submissions exploring topics on  AI classification of dementia subtypes  AI prediction of AD conversion and dementia disease progression  AI MRI of... see more

Submission closes on: Aug 20, 2024
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease

Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address the complex challenges posed by Alzheimer's disease. Aims: . Explore Emerging Preventive Measures: Investigate novel strategies and interventions aimed at preventing or delaying the onset... see more

Submission closes on: Jul 28, 2024
Linear and non-linear Signals from the brain: from basic to clinical application

Neurodegenerative diseases are increasing in the general population and have been defined by the World Health Organization (WHO) and Alzheimer's Disease International (ADI) as a global public health priority. Data from the WHO Global Action Plan 2017-2025 indicates that in 2015, neurodegeneration-related diseases affected 47 million people worldwide, a figure expected to increase to 75 million by 2030 and 132 million by 2050, with approximately 10 million new cases per year (1 every 3 seconds).... see more

Submission closes on: Jun 23, 2024
Virtual reality-based interventions for cognitive rehabilitation in Alzheimer’s disease

Virtual reality (VR) has been a widely used tool for the rehabilitation of patients in the last two decades, both in the motor and cognitive aspects. VR-based applications are a form of non-pharmacological therapy that has proven effective as an adjuvant treatment. VR has also been shown to be a tool that can improve the quality of life and well-being of people with dementia. Although great progress has been made in the motor aspect, there... see more